JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB141399

Ethacrynic acid, Glutathione S-transferase (GST) inhibitor

Be the first to review this product! Submit a review

|

(1 Publication)

MW 303.13 Da, Purity >99%. Achieve your results faster with highly validated, pure and trusted compounds.

View Alternative Names

(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, CP2C9_HUMAN, CPC9, CYP2C, CYP2C10, CYPIIC9, Cytochrome P-450MP, Cytochrome P450 2C9, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 PB-1, Cytochrome P450, family 2, subfamily C, polypeptide 9, MGC149605, MGC88320, Microsomal monooxygenase, NF-E2-related factor 2, NF2L2_HUMAN, NRF2, Nfe2l2, Nuclear factor, Nuclear factor (erythroid derived 2) like 2, Nuclear factor erythroid 2-related factor 2, Nuclear factor erythroid derived 2 like 2, OTTHUMP00000020135, P450 MP, P450 PB 1, P450IIC9, S-mephenytoin 4-hydroxylase, Xenobiotic monooxygenase, cytochrome P-450 S-mephenytoin 4-hydroxylase, erythroid derived 2, flavoprotein-linked monooxygenase, like 2, nuclear factor erythroid 2 like 2

1 Images
Chemical Structure - Ethacrynic acid, Glutathione S-transferase (GST) inhibitor (AB141399)
  • Chemical Structure

Lab

Chemical Structure - Ethacrynic acid, Glutathione S-transferase (GST) inhibitor (AB141399)

2D chemical structure image of ab141399, Ethacrynic acid, Glutathione S-transferase (GST) inhibitor

Key facts

CAS number

58-54-8

Purity

>99%

Form

Solid

form

Molecular weight

303.13 Da

Molecular formula

C<sub>1</sub><sub>3</sub>H<sub>1</sub><sub>2</sub>Cl<sub>2</sub>O<sub>4</sub>

PubChem

3278

Nature

Synthetic

Solubility

Soluble in ethanol to 100 mM

Soluble in DMSO to 100mM

Biochemical name

Ethacrynic acid

Canonical smiles

CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl

InChi

InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)

InChiKey

AVOLMBLBETYQHX-UHFFFAOYSA-N

IUPAC Name

2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CYP2C9 also known as Cytochrome P450 2C9 is an enzyme that plays a significant role in drug metabolism. It is a member of the cytochrome P450 superfamily with a molecular mass of approximately 55 kDa. The enzyme is predominantly found in the liver where it contributes to the oxidation of various substrates including drugs cholesterol and other lipids. It is an important target in pharmacogenomics due to its influence on drug clearance and interaction.
Biological function summary

CYP2C9 participates in the phase I metabolism of xenobiotics and endogenous compounds. It is not part of a larger complex but works closely with other enzymes to sustain metabolic processes. CYP2C9 converts lipophilic molecules into more hydrophilic forms which facilitates their subsequent conjugation and elimination. Its activity affects the pharmacokinetics and pharmacodynamics of nonsteroidal anti-inflammatory drugs (NSAIDs) and oral anticoagulants.

Pathways

CYP2C9 is essential in the arachidonic acid metabolism and steroid hormone biosynthesis pathways. In these pathways it interacts with other cytochrome P450 enzymes like CYP3A4 to metabolize drugs and steroids. The synergy between CYP2C9 and related enzymes ensures efficient metabolic clearance of drugs and bioactive lipids although it can also lead to drug interactions if multiple drugs are metabolized by the same enzyme.

CYP2C9 polymorphisms have been linked to altered drug metabolism particularly affecting therapeutic outcomes in cardiovascular conditions and epilepsy. Variants of CYP2C9 can lead to increased or decreased metabolism of warfarin commonly used in cardiovascular disease management. Disorders related to CYP2C9 activity often involve impaired clearance of therapeutic agents and are also seen in conjunction with variations in other metabolic enzymes such as GST (glutathione S-transferase).

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Cancers 13: PubMed34680344

2021

SIRT3 and Metabolic Reprogramming Mediate the Antiproliferative Effects of Whey in Human Colon Cancer Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Nunzia D'Onofrio,Elisa Martino,Anna Balestrieri,Luigi Mele,Gianluca Neglia,Maria Luisa Balestrieri,Giuseppe Campanile
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com